After first-line approval in DLBCL, debate continues around benefit from Roche’s ADC Polivy

The FDA approved Roche and Genentech’s antibody-drug conjugate Polivy in April as a first-line treatment for diffuse large B-cell lymphoma (DLBCL) alongside a chemotherapy regimen R-CHP.

The approval came despite modest efficacy in a Phase III study and FDA questions about the therapy, though…
Click here to view original post